Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa
Sponsor: MoonLake Immunotherapeutics AG
Listed as NCT05322473, this PHASE2 trial focuses on Hidradenitis Suppurativa and remains completed. Sponsored by MoonLake Immunotherapeutics AG, it has been updated 13 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jun 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MoonLake Immunotherapeutics AG
For direct contact, visit the study record on ClinicalTrials.gov .